Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vigil Neuroscience, Inc. - Common Stock (NQ: VIGL )

1.770 -0.070 (-3.80%)
Streaming Delayed Price Updated: 3:27 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vigil Neuroscience, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 283 companies set new 52-week lows. 
Via Benzinga
Vigil Neuroscience: Q1 Earnings Insights
Via Benzinga
What 4 Analyst Ratings Have To Say About Vigil Neuroscience
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 155 companies set new 52-week lows. 
Via Benzinga
Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Appoints Christopher J. Silber, M.D. as Chief Medical Officer
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth. 
Via MarketBeat
Topics Retirement
Exposures Pension
Vigil Neuroscience to Present at 2023 Jefferies Global Healthcare Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023
Via Benzinga
Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101
Company remains on track to report interim data from Phase 2 trial in the second half of 2023 
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider. 
Via Benzinga
BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Vigil Neuroscience to Present at Stifel 2023 CNS Days
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Announces Multiple Presentations on Lead Indication ALSP at the 2023 American Academy of Neurology Annual Meeting
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals, Xylem And Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones gaining over 300 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
AMC Preferred Equity Units, Accolade And Some Other Big Stocks Moving Higher On Friday
U.S. stocks traded mixed, with the Dow Jones gaining over 50 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why IceCure Medical Shares Are Trading Higher By 296%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 296% to $3.71 after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who... 
Via Benzinga
Arcus Biosciences, FuelCell Energy And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Vigil Neuroscience Appoints David Gray, Ph.D., as Chief Scientific Officer and Announces Changes to Executive Team
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSP
First-ever interventional trial for patients with ALSP, a rare and rapidly progressing neurological disease with significant unmet medical need 
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Host ALSP KOL Event on December 6, 2022
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Carvana, Crocs And Other Big Losers From Monday
U.S. stocks closed lower on Monday, with the Nasdaq dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Why TuanChe Shares Are Trading Lower By 76%? Here Are 48 Stocks Moving In Monday's Mid-Day Session
Gainers Imago BioSciences, Inc. (NASDAQ: IMGO) shares jumped 104% to $35.50 after Merck announced it would acquire the company for $36 per share in cash. 
Via Benzinga
Why Drive Shack Shares Jumped Over 23%; Here Are 76 Biggest Movers From Yesterday
Gainers Imago BioSciences, Inc. (NASDAQ: IMGO) shares climbed 104.5% to close at $35.59 on Monday after Merck announced it would acquire the company for $36 per share in cash. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.